PTPN1 and cancer: More recently, ABB-CLS-484,a dual PTP1B/TCPTP inhibitor, progressed to Phase II clinical trialsas an immunotherapeutic., Given the growing interestin PTP1B inhibitors for cancer immunotherapy, the continued discoveryof new potent drug-like scaffolds remains essential.